JPWO2019230645A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019230645A5 JPWO2019230645A5 JP2020522178A JP2020522178A JPWO2019230645A5 JP WO2019230645 A5 JPWO2019230645 A5 JP WO2019230645A5 JP 2020522178 A JP2020522178 A JP 2020522178A JP 2020522178 A JP2020522178 A JP 2020522178A JP WO2019230645 A5 JPWO2019230645 A5 JP WO2019230645A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- therapeutic agent
- agent according
- cancer
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 26
- 229940124597 therapeutic agent Drugs 0.000 claims 23
- 230000035772 mutation Effects 0.000 claims 20
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 19
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 239000000611 antibody drug conjugate Substances 0.000 claims 7
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 230000027455 binding Effects 0.000 claims 3
- 238000009739 binding Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 102220042680 rs116440799 Human genes 0.000 claims 2
- 102220285398 rs1553637262 Human genes 0.000 claims 2
- 102200068497 rs35469582 Human genes 0.000 claims 2
- 102220004843 rs397516975 Human genes 0.000 claims 2
- 102220004844 rs587776805 Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102220014234 rs397516981 Human genes 0.000 claims 1
- 102200031502 rs62642913 Human genes 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018101211 | 2018-05-28 | ||
| JP2018101211 | 2018-05-28 | ||
| JP2018177132 | 2018-09-21 | ||
| JP2018177132 | 2018-09-21 | ||
| PCT/JP2019/020886 WO2019230645A1 (ja) | 2018-05-28 | 2019-05-27 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2019230645A1 JPWO2019230645A1 (ja) | 2021-07-08 |
| JPWO2019230645A5 true JPWO2019230645A5 (https=) | 2022-06-06 |
| JP7441165B2 JP7441165B2 (ja) | 2024-02-29 |
Family
ID=68698185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522178A Active JP7441165B2 (ja) | 2018-05-28 | 2019-05-27 | 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210205466A1 (https=) |
| EP (1) | EP3804764A4 (https=) |
| JP (1) | JP7441165B2 (https=) |
| KR (2) | KR20210014660A (https=) |
| CN (2) | CN112153989B (https=) |
| AU (1) | AU2019278628B2 (https=) |
| BR (1) | BR112020024061A2 (https=) |
| IL (1) | IL278988B2 (https=) |
| SG (1) | SG11202011243XA (https=) |
| TW (1) | TW202015738A (https=) |
| WO (1) | WO2019230645A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018320470B2 (en) * | 2017-08-23 | 2025-04-24 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
| CN111088353A (zh) * | 2019-12-27 | 2020-05-01 | 浙江大学 | 帕妥珠单抗耐药性突变的应用、检测试剂盒及检测方法 |
| JP7848119B2 (ja) | 2020-07-20 | 2026-04-20 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ |
| WO2023072006A1 (zh) * | 2021-10-25 | 2023-05-04 | 黄�俊 | 多聚体在car表达细胞检测和细胞制备中的应用 |
| CN115957321A (zh) * | 2023-03-03 | 2023-04-14 | 盛禾(中国)生物制药有限公司 | 一种抗her2抗体在制备治疗癌症的药物中的用途 |
| CN116930497B (zh) * | 2023-06-27 | 2024-02-06 | 广东省第二人民医院（广东省卫生应急医院） | 检测外泌体HER2膜蛋白和mRNA的试剂盒及其应用和检测方法 |
| WO2025242061A1 (zh) * | 2024-05-21 | 2025-11-27 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物治疗胆道癌的用途 |
| WO2025252039A1 (zh) * | 2024-06-03 | 2025-12-11 | 正大天晴药业集团股份有限公司 | 抗her2抗体药物偶联物治疗非小细胞肺癌的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| CN116059395A (zh) * | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| KR20190066026A (ko) * | 2016-10-07 | 2019-06-12 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료 |
-
2019
- 2019-05-27 IL IL278988A patent/IL278988B2/en unknown
- 2019-05-27 BR BR112020024061-3A patent/BR112020024061A2/pt unknown
- 2019-05-27 KR KR1020207037050A patent/KR20210014660A/ko not_active Ceased
- 2019-05-27 EP EP19812523.9A patent/EP3804764A4/en active Pending
- 2019-05-27 CN CN201980035852.5A patent/CN112153989B/zh active Active
- 2019-05-27 JP JP2020522178A patent/JP7441165B2/ja active Active
- 2019-05-27 SG SG11202011243XA patent/SG11202011243XA/en unknown
- 2019-05-27 KR KR1020257020972A patent/KR20250105480A/ko active Pending
- 2019-05-27 US US17/058,838 patent/US20210205466A1/en active Pending
- 2019-05-27 AU AU2019278628A patent/AU2019278628B2/en active Active
- 2019-05-27 CN CN202510942573.4A patent/CN120501882A/zh active Pending
- 2019-05-27 WO PCT/JP2019/020886 patent/WO2019230645A1/ja not_active Ceased
- 2019-05-28 TW TW108118348A patent/TW202015738A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019230645A5 (https=) | ||
| ES2941768T3 (es) | Compuestos de 2H-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (TLR7) y métodos y usos para los mismos | |
| TWI868726B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| JP2025041725A5 (https=) | ||
| JPWO2020031936A5 (https=) | ||
| ES2929637T3 (es) | Complejo de ácido peptidonucleico que tiene permeabilidad celular mejorada y composición farmacéutica que comprende el mismo | |
| ES2905842T3 (es) | Derivados de 6-amino-7,9-dihidro-8h-purin-8-ona como agonistas del receptor tipo Toll 7 (TLR7) como inmunoestimulantes | |
| JPWO2020122034A5 (https=) | ||
| CN113271942A (zh) | 抗体-药物缀合物与parp抑制剂的组合 | |
| JP2010539981A5 (https=) | ||
| CA3047359A1 (en) | Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy | |
| JP2022095908A5 (https=) | ||
| CN110650750A (zh) | 基于肽的疫苗、其制造方法及其用于诱导免疫应答的用途 | |
| AU2019278628B2 (en) | Treatment of HER2-mutated cancer by administering anti-HER2 antibody-drug conjugate | |
| KR102230325B1 (ko) | 면역 부활 활성을 갖는 핵산 유도체 | |
| JP2023527962A5 (https=) | ||
| JP2016536342A5 (https=) | ||
| JP2017521090A5 (https=) | ||
| EA027925B1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
| JPWO2022102634A5 (https=) | ||
| US20200297693A1 (en) | Glucose conjugates of triptolide, analogs and uses thereof | |
| TWI641385B (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JPWO2020027100A5 (https=) | ||
| WO2016115218A1 (en) | Antibody drug conjugates for the treatment of immune conditions | |
| IL302812A (en) | Antibody-drug conjugate combinations with anti-SIRP alpha antibody |